Abstract: Novel compounds of the structural formula (I), and pharmaceutically acceptable salts, hydrates and solvates thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of structural formula I may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.
Type:
Application
Filed:
May 30, 2024
Publication date:
December 5, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Zachary G. Brill, Chen Cheng, Donna A.A.W. Hayes, Kyle S. McClymont, Rohan Rajiv Merchant, Maoqun Tian
Abstract: Compounds of formula I, that modulate DCAF15 and induce RBM139 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity and DCAF15 modulation are described herein.
Type:
Application
Filed:
October 7, 2022
Publication date:
December 5, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
John P. Caldwell, Ping Lan, Hongwu Wang, Paul Wehn
Abstract: The present invention relates to excipients for special protein formulations, which are suitable to improve the thermal stability against denaturation and deactivation. In particular, the present invention relates to additives for thermostabilizing of vaccine formulations.
Abstract: A polymerisable liquid crystal (LC) compound, a corresponding polymerizable LC material, a polymer film with flat, negative, or positive optical dispersion obtainable from such a material, and the use of the polymerisable LC, polymerisable LC material and/or polymer film in optical, electro optical, electronic, semiconducting, or luminescent components or devices.
Type:
Application
Filed:
October 10, 2022
Publication date:
December 5, 2024
Applicant:
MERCK PATENT GmbH
Inventors:
Kevin Adlem, Martin Heeney, James Allen
Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
Type:
Grant
Filed:
May 9, 2018
Date of Patent:
December 3, 2024
Assignees:
TESARO, Inc., MERCK SHARP & DOHME B.V.
Inventors:
Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
Abstract: The invention relates to novel compounds and formulations. Further, the invention relates to novel compounds and formulations useful in pneumococcal and pneumococcal conjugate vaccines. More specifically, the invention relates to compositions comprising pneumococcal conjugates and one or more compounds of Formula I, Ia, II, IIa, III, IIIa, IV, or IVa, or a pharmaceutically acceptable salt thereof, prepared as stable nanoemulsions (herein referred to as “SNE adjuvant compositions” or “SNEs”).
Type:
Application
Filed:
May 16, 2024
Publication date:
November 28, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Patrick L. Ahl, Peter J. Manley, Izzat T. Raheem, W. Michael Seganish, William J. Smith
Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
Type:
Grant
Filed:
October 11, 2019
Date of Patent:
November 26, 2024
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Jongwon Lim, Theodore A. Martinot, Alexander Pasternak, Li Xiao, Wensheng Yu
Abstract: Compounds of formula (I) are made, wherein W1, W2, W3, W4, R1, R2, R3, R4, R5, R6 and m have the meaning as described herein. The compounds are SRPK inhibitors and can be used, inter alia, for the treatment of hyperproliferative disorders. A medicament and a pharmaceutical composition are made that include the compound of formula (I). Methods are developed for treating a disease caused, mediated, and/or propagated by SRPK activity, for preparing a medicament for the treatment thereof, and for inhibiting SRPK.
Abstract: Substituted tetrazole derivatives are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
Type:
Application
Filed:
August 2, 2024
Publication date:
November 21, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Chitrananda Abeygunawardana, Yadong Adam Cui, Romulo Ferrero, Jian He, Luwy Musey, Tanaz Petigara, Julie M. Skinner
Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form comprising mesoporous silica using a 3D printing process. The process is a printing process that allows the production of solid pharmaceutical administration forms comprising drug loaded mesoporous silica in an easy and flexible manner and in conformity with the high-quality standards required for the production of pharmaceutical.
Type:
Application
Filed:
July 5, 2022
Publication date:
November 21, 2024
Applicant:
Merck Patent GmbH
Inventors:
Malte BOGDAHN, Stefan SCHILLER, Meike HARMS, Daniel Joseph PRICE, Marcel WEDEL, Simon GEISSLER, Finn BAUER
Abstract: A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized in the form of lyospheres of carrier protein and lyospheres of the one or more polysaccharides. A predetermined amount of carrier protein lyospheres and activated polysaccharide lyospheres are mixed together and the mixture reconstituted in an organic solvent to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.
Type:
Grant
Filed:
April 25, 2019
Date of Patent:
November 19, 2024
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Patrick Leonard Ahl, Akhilesh Bhambhani, Christopher Jon Farrell, Patrick McHugh, Morrisa C. Jones, Daniel D. Roth, Jessica R. Sinacola, Justin Stanbro, Matthew P. Watson, Emily Wen, Michael A. Winters
Abstract: The invention described herein relates to a high-throughput and multiplex Streptococcus pneumoniae (S. pneumoniae) serotype (ST)-specific polymerase chain reaction-pneumococcal antigen detection (PCR-PAD) assay useful to support epidemiology studies, clinical trials and clinical therapy. The invention further provides kits for detecting the presence or absence of S. pneumoniae and the presence or absence of particular S. pneumoniae strains in a patient sample.
Type:
Application
Filed:
April 23, 2024
Publication date:
November 14, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Kate L. Hicks, Gowrisankar Rajam, Leonard J. Rubinstein
Abstract: A liquid-crystalline medium, preferably having a nematic phase, comprising one or more compounds of formula C the use thereof in an energy-efficient electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, displays of this type which contain a liquid-crystalline medium of this type, and the use of the compounds of formula C for improvement of the contrast and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds.
Type:
Application
Filed:
December 20, 2021
Publication date:
November 14, 2024
Applicant:
Merck Patent GmbH
Inventors:
Sven Christian Laut, Martina Windhorst, Atsutaka Manabe, Constanze Brocke
Abstract: The present invention relates to methods for treating diseases and conditions characterised by aberrant cell growth, e.g., cancers, comprising administering a combination of a DNA repair inhibitor and a molecular targeted radioimmunotherapeutic agent.
Abstract: The present invention is directed to nucleic acids and related immunogenic polypeptides for the prevention or treatment of infectious diseases. In particular, the nucleic acids and immunogenic polypeptides provide utility for the prophylactic prevention of norovirus infections in a mammal. The invention is further directed to nucleic acid-based vaccine compositions and a kit of parts comprising the vaccine compositions, as well as methods of treatment and medical uses relating to the nucleic acids, vaccine compositions, and kit of parts.
Type:
Application
Filed:
May 6, 2024
Publication date:
November 14, 2024
Applicant:
Merck Sharp & Dohme LLC
Inventors:
Lauren A. Austin, Andrew Bett, Arthur Fridman, JiaJie Wei, John Gaspar, Marian E. Gindy
Abstract: A novel treatment regimen is provided for the treatment of autoimmune disorders. Said novel treatment regimen provides for an efficacious treatment of autoimmune disorders with an advantageous safety profile and/or a high quality of life for the patient. Said novel treatment regimen provides for an advantageous benefit-risk ratio for patients endangered by the risk of infections.
Abstract: An electronic element (10) comprising a plurality of cells (100) arranged in a three dimensional array of cells (100) is provided, wherein the cells (100) are located at crossings between two crossed electrode lines (30, 31). Each cell (100) of the electronic component (100) comprises in this order a first electrode (102), a part (104) of a molecular layer (20) and a second electrode (106), wherein the molecular layer (20) is a self-assembled monolayer of organic molecules having an anchoring group connected to a dipolar unit by means of a conformationally flexible unit. Further aspects of the invention relate to a method and a compound for producing such an electronic element (10) and the use of such an electronic element (10).
Type:
Application
Filed:
June 7, 2022
Publication date:
November 14, 2024
Applicant:
MERCK PATENT GMBH
Inventors:
Peer KIRSCH, Sebastian RESCH, Henning SEIM, Marc TORNOW